Danaher vs. Medtronic: Which Stock Has More Upside Now?
Two healthcare giants, one recovery trade. Here's how Danaher and Medtronic stack up for investors hunting upside.
Healthcare is back on traders' radars, and two names keep coming up in the same breath: Danaher and Medtronic. Both have been through the wringer over the past couple of years, and both are pitching themselves as recovery stories. But recovery stories aren't created equal — and only one of them is likely to reward you more for the risk you're taking on.
Danaher built its reputation as a precision instruments and life-sciences powerhouse, but the post-pandemic biotech spending hangover hit it hard. The stock pulled back significantly from its highs as lab and diagnostic demand normalized. The bull case here is that life-sciences capex has to come back eventually, and when it does, Danaher is positioned right at the front of that spending pipeline.
Read more Pemex and Petrobras Double Down on Risky Mexico Offshore Drilling →
Medtronic, on the other hand, is a pure-play medical devices story. It's been grinding through an operational reset — trimming its portfolio, pushing new product cycles, and trying to convince Wall Street that its margins can actually expand from here. The company has struggled to generate the kind of growth that gets growth investors excited, but value-oriented traders see a dividend-paying stalwart trading at a discount to its historical multiples.
The honest comparison here comes down to what kind of trader you are. If you want leverage to a biotech and life-sciences spending rebound, Danaher gives you that torque. If you want a steadier, dividend-cushioned recovery with lower volatility, Medtronic fits that profile. Neither is a slam dunk, but the macro setup — stabilizing interest rates and recovering hospital capital budgets — creates a real tailwind for both names heading into the back half of the year.
The smarter move is knowing which recovery timeline matches your own. Don't just buy the sector — buy the story that fits your thesis. Continue reading at Yahoo Finance.
